This paper describes the high concentration of mucina 16 (muc16) in ovarian cancer, and shows that the expression of cancer cells protects tumor cells in the immune system. The present invention provides a new human immunodeficiency virus (IgG) antibody to prevent human C16 (monomer antibody). The present invention also provides new biological antibodies, which are designated as C16 and CD3, and activate lymphocytes through the CD3 complex in the case of biological C16 tumor. According to some implementations,The present invention provides for the immobilization of bicarbonate antigens, including the first antigen immobilization site specifically for a third human and monkey, and the second antigen immobilization molecule specifically for a sixth human and monkey. In some implementations,The solidified molecules of two antigens in the invention may inhibit the growth of carcinogen C16. The solidifying molecules of the two antigens have been developed to help treat diseases and disorders for which a bottom-up induced or controlled immune response is desirable and / or therapeutic advantage. For example, the double antibody invented is useful for the treatment of various cancers.These include ovarian cancer. The present invention also includes anti adhesive muc16 antibody, which can inhibit the growth of living tumor. In some embodiments, an anti-c16 antibody may be useful for diagnostic methods to determine the presence of C16 in tissue and / or plasma samples.RESUMEN La mucina 16 (MUC16) se expresa en niveles altos en el cáncer de ovario y se muestra que la expresión en células cancerosas protege a las células tumorales del sistema inmunológico. La presente invención proporciona anticuerpos contra IgG humana de longitud completa novedosos que se fijan a anti-MUC16 humano (anticuerpos monoespecíficos). La presente invención también proporciona anticuerpos biespecíficos (bsAbs) novedosos que se fijan a MUC16 y CD3, y activan los linfocitos T a través del complejo CD3
